Cargando…

A Case of Cobalamin Deficiency and Macrocytic Anemia Secondary to Sunitinib

Sunitinib is an oral tyrosine kinase inhibitor (TKI) commonly used in the treatment of renal cell carcinoma (RCC). Among a broad range of toxicities, anemia and macrocytosis are common in patients treated with sunitinib. Correlation between sunitinib-associated macrocytosis and cobalamin deficiency...

Descripción completa

Detalles Bibliográficos
Autores principales: Reed, Jarred P, Chung, Joan, Banerjee, Natasha
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6538120/
https://www.ncbi.nlm.nih.gov/pubmed/31183290
http://dx.doi.org/10.7759/cureus.4310

Ejemplares similares